Who Owns Axsome Company?

Axsome Bundle

Get Full Bundle:

	5 FORCES	$15	$10
	BCG	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10
	SWOT	$15	$10

TOTAL:

ADD TO CART

Who owns Axsome Therapeutics?

Axsome Therapeutics moved to commercial-stage prominence with Auvelity in 2022, prompting investor focus on ownership, governance, and capital strategy. Founded in 2012 and listed as NASDAQ: AXSM, Axsome targets CNS disorders with a capital-efficient R&D model.

Ownership is split among founders/insiders, institutional investors and index funds, plus public float; 2024 revenue topped $300 million, led by Auvelity. See Axsome Porter's Five Forces Analysis for strategic context.

Founders and early ownership at Axsome centered on Herriot Tabuteau, MD as founder and CEO, with Mark Jacobson as an early executive; initial equity concentrated with Tabuteau to anchor long‑term CNS strategy while option pools were set for key hires.

Founding leadership

Herriot Tabuteau founded Axsome in 2012 and maintained a controlling stake pre‑IPO to protect strategic focus on CNS programs.

Early executive team

Mark Jacobson provided corporate development and strategic finance experience during early company formation and fundraising.

Seed and friends‑and‑family

Initial capital came from friends‑and‑family and seed investors with CNS development knowledge supporting IND and Phase 2 progression.

Pre‑IPO investors

Crossover and biotech‑specialist investors joined in the pre‑IPO rounds, preparing the company for public markets and larger financing needs.

Equity incentives

Standard founder vesting schedules and an equity incentive plan were established; internal option pools rewarded executives and key hires.

Governance protections

Typical venture biotech provisions—four‑year vesting with one‑year cliffs, ROFRs, buy‑sell and co‑sale rights—were adopted to stabilize control.

Public filings around the 2015–2016 IPO show Tabuteau held a controlling position pre‑offering and no major founder disputes were recorded; for context and chronology see Brief History of Axsome.

Key points on early ownership

Founders, structure and investor mix that defined Axsome’s early control and capitalization.

• Founder control: Herriot Tabuteau retained a controlling stake pre‑IPO to preserve CNS focus.
• Early executives: Mark Jacobson led corporate development/strategic finance functions during formation.
• Investor progression: friends‑and‑family and seed investors → biotech specialists and crossover pre‑IPO.
• Governance: standard venture biotech vesting and ROFR/co‑sale provisions implemented to stabilize ownership.

Axsome SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

Key financing, clinical readouts and M&A between 2015 and 2024 reshaped Axsome ownership from founder-majority control at IPO to an institutionally weighted register by 2025, driven by follow-on offerings, commercialization of Auvelity and the Sunosi acquisition.

Ownership evolution moved governance influence from founder-centric toward institutional moderation, with top institutions and passive funds becoming dominant holders while retail and employee equity remained meaningful for liquidity and alignment.

Ownership composition snapshot

Tableau of major stakeholder categories and their typical roles in corporate strategy and capital markets.

• Founder/CEO Herriot Tabuteau, MD — ongoing insider exposure via common shares and options; material but non‑controlling stake
• Large passive index funds — Vanguard, BlackRock, State Street driving stable base and voting scale
• Biotech specialists — RA Capital, Perceptive, RTW (periodic) providing sector conviction and active engagement
• Public float, retail and employees — provide trading liquidity and equity compensation alignment

Representative facts from public filings: post‑IPO founder/insider ownership fell from majority levels to a significant minority after multiple follow‑on financings; 13F filings from 2021–2024 show Vanguard and BlackRock among top holders, while combined top‑10 institutional ownership commonly represents a substantial minority to majority share of float in similar peers — Axsome mirrors this institutional concentration as it transitioned to a commercial, mid‑cap company (see Target Market of Axsome for related commercial context).

Axsome PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

As of 2025 the Axsome board combines founder‑leadership with independent directors experienced in CNS drug development, commercialization and public‑company finance; board seats are largely independent and reflect dispersed institutional ownership rather than a controlling sponsor.

Axsome operates on a one-share-one-vote model with no public disclosure of dual‑class or super‑voting shares; control arises from insider equity stakes and executive leadership rather than special voting rights, and recent governance has emphasized commercialization execution, pricing/access, and pipeline prioritization rather than proxy conflicts.

Board composition and voting power highlights

Board mix supports clinical and commercial execution while preserving independent oversight; voting power follows equity ownership without special voting classes.

• Founder representation: Herriot Tabuteau, MD serves on the board and holds executive authority
• No disclosed golden share or super‑voting structure; governance uses one‑share‑one‑vote
• Seats are mainly independent, not investor‑designated, reflecting dispersed institutional investors
• Major governance focuses: commercialization, pricing/access, pipeline prioritization; no recent high‑profile proxy battles

For context on commercial strategy interplay with governance see Marketing Strategy of Axsome; institutional ownership remained concentrated among mutual funds and ETFs per 13F filings, with top holders (BlackRock, Vanguard, State Street) collectively often exceeding 30% of shares and insider ownership including executive holdings typically reported in the low‑single digits to teens as percent of outstanding stock in recent SEC beneficial ownership filings.

Axsome Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

From 2022 through 2025 Axsome ownership shifted toward larger institutional and index positions as the company scaled commercialization, increasing liquidity and analyst coverage; insider stakes were modestly diluted by opportunistic follow-on financings while voting remained one-share-one-vote.

Ownership now reads as widely held with institutional dominance and sustained but non-controlling insider influence, reflecting a capital-efficient approach to late-stage development and commercial scaling; see Competitors Landscape of Axsome for context on sector positioning and potential shareholder interest.

Institutional concentration

By 2025 institutional ownership rose to a majority of publicly reported float in many 13F filings, increasing Axsome major shareholders visibility and liquidity.

Financing cadence

Follow-on financings around milestones modestly diluted insiders but extended runway for AXS-05, AXS-07 and AXS-14 programs alongside Auvelity/Sunosi commercialization.

Insider selling

Insider selling has been periodic and typically executed under 10b5-1 plans, reflecting liquidity needs rather than shifts in control or major insider ownership change.

M&A and strategic flows

Sunosi-based revenue diversification attracted generalist growth funds; future licensing or partnerships could bring strategic holders but not a controlling block.

Axsome Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔